Second Line Erlotinib for NSCLC Patients with EGFR Mutation: Our Experience
Latest Information Update: 19 Oct 2015
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 19 Oct 2015 New trial record
- 06 Sep 2015 Results presented at the 16th World Conference on Lung Cancer.